PUBLIC COMPANY
saveASCENDIS
USupdated 4mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 3d ago
- Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest dealPlus news about Corbus, Syntis, Arrowhead, BioMarin, BioVie, Agomab, Antelope Therapeutics, Connect Biopharma and Genfit. Rocket Pharmaceuticals aligns with FDA on Danon: The commercial-stage biote…endpoints · 3d ago
- Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisNovo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…fiercebiotech · 4d ago
- UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapyPlus, news about Regeneron, Novocure, Jazz's Ziihera, BioMarin, Ascendis, AstraZeneca, Hutchmed and TScan Therapeutics. Another road bump for Tavneos: The Medicines and Healthcare products Regulato…endpoints · 16d ago
- Teva claims success in celiac study; BioMarin, Ascendis settle patent disputeTeva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.biopharma_dive · 16d ago
- Biomarin nabs big royalties in achondroplasia patent settlement with AscendisBiomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…biospace · 18d ago
- BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indicationBioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.biospace · 1mo ago
comments(0)
5-min edit window · permanent after that